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Abstract
Infectious disease has recently joined poaching and habitat loss as a major threat to African apes. Both ‘‘naturally’’ occurring
pathogens, such as Ebola and Simian Immunodeficiency Virus (SIV), and respiratory pathogens transmitted from humans,
have been confirmed as important sources of mortality in wild gorillas and chimpanzees. While awareness of the threat has
increased, interventions such as vaccination and treatment remain controversial. Here we explore both the risk of disease to
African apes, and the status of potential responses. Through synthesis of published data, we summarize prior disease impact
on African apes. We then use a simple demographic model to illustrate the resilience of a well-known gorilla population to
disease, modeled on prior documented outbreaks. We found that the predicted recovery time for this specific gorilla
population from a single outbreak ranged from 5 years for a low mortality (4%) respiratory outbreak, to 131 years for an
Ebola outbreak that killed 96% of the population. This shows that mortality rates comparable to those recently reported for
disease outbreaks in wild populations are not sustainable. This is particularly troubling given the rising pathogen risk
created by increasing habituation of wild apes for tourism, and the growth of human populations surrounding protected
areas. We assess potential future disease spillover risk in terms of vaccination rates amongst humans that may come into
contact with wild apes, and the availability of vaccines against potentially threatening diseases. We discuss and evaluate
non-interventionist responses such as limiting tourist access to apes, community health programs, and safety, logistic, and
cost issues that constrain the potential of vaccination.
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Introduction
Poaching and habitat loss are known major threats to African
apes [1], but what has only in the last few years come into focus is
that infectious disease is a threat of similar magnitude. Wild
populations of gorillas and chimpanzees are threatened by a
diverse array of virulent pathogens, including Ebola virus [1,2],
Anthrax [3], simian immunodeficieny virus (SIV) [4], and a
variety of human respiratory viruses [5,6]. These recent
illustrations of the magnitude of disease threat have intensified a
longstanding debate about the advisability of medical interventions
such as vaccination. The dissent seems to hinges on two major
points, one on the ethics of intervening in ‘‘natural’’ systems and
the other on the magnitude of threat and cost effectiveness of
vaccination relative to other conservation strategies.
Our goal is to explore the potential impact of disease outbreaks
on African great apes, and the available interventions, such as
vaccination and treatment, as practical conservation strategies.
More precisely, our objective is to provide a scientifically based
discussion about the need for, feasibility and cost effectiveness of
intervention for disease threats in African apes.
1. We present an overview of previous studies to review
pathogens known to have infected wild African apes, and
describe the population impact they are known to have had, to
allow the reader to gauge the magnitude of the disease threat.
2. We parameterize a simple demographic model to project the
time scales over which a well-known gorilla population would
recover from outbreaks of known previous diseases, to illustrate
how little resilience ape populations have to disease. 3. We then
assess future disease risk, in terms of the prevalence of several
potentially dangerous pathogens in human populations and the
rates of vaccination against them, both in African ape range
states and in a typical source country for ape tourism programs.
4. We synthesize the available literature and reports on current
vaccine status for both apes and humans, for diseases known to
impact great apes. We then discuss and compare approaches to
mitigating disease impact on wild apes, from behavior
guidelines for tourist and staff to local human community
health programs to ape health intervention measures. We then
focus our discussion on efforts to treat wild apes for disease and
compare these to the potential vaccination has for protecting
wild apes against disease, including the status of available
human vaccines. We address the practicalities of vaccination,
including safety, cost, and vaccine delivery, and close with some
thoughts on the ethics of vaccination and other medical
interventions.
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Pathogens that threaten wild gorillas and chimpanzees fall into
three broad classes, pathogens that circulate persistently in other
forest animals (sylvatic pathogens) then occasionally spill over into
apes, pathogens that spillover from humans (reverse zoonotic
pathogens), and pathogens that circulate persistently within wild
ape populations (enzootic pathogens). Perhaps the best known
pathogen to recently threaten African apes is the Ebola Virus.
Over the last two decades the Zaire strain of Ebola has killed
roughly one third of the world’s gorilla population and only a
slightly smaller proportion of the world’s chimpanzees [1,2,7].
Although these large Ebola Zaire outbreaks in great apes have
been documented only in Gabon and the Republic of Congo [8,9],
chimpanzees in Ivory Coast have been killed by another strain,
Ebola Cote d’Ivoire [10].
Human filovirus outbreaks have also occurred in several other
African ape range states, including Angola (Marburg virus) [11],
Democratic Republic of Congo (Ebola Zaire and Marburg virus)
[12,13], and Uganda (Marburg Virus, Ebola Sudan and the newly
discovered Bundibugyo strain of Ebola) [14,15,16]. The 2007
human outbreaks of Ebola Bundibugyo occurred close to several
chimpanzee populations: Semliki National Park (12 km away),
Rwenzori National Park (36 km away), Toro (Semliki) Game
Reserve (41 km), and Kibale National Park (47 km away), and
Marburg virus was detected in bats living at Kitaka Caves, 65 km
south of Kibale [17].
The first evidence that enzootic diseases also pose a threat to
wild apes was also reported in 2009. A combination of clinical
observations, demographic analyses, and pathogen assays showed
that simian immunodeficiency virus (SIV) is not non-virulent in
chimpanzees, as previously suggested by captive studies. Rather,
wild, SIV infected chimpanzees showed AIDS-like symptoms,
birth rates about one third of uninfected animals, and annual
mortality rates about ten times higher [4]. These observations raise
the concern that other pathogens known to persistently infect wild
apes, such as simian foamy viruses [18], hepatitis B [19] regularly
circulating adenoviruses [20] and malaria [21] may also negatively
influence birth or survival rates.
It is increasingly clear that a number of pathogens spilling over
from humans represent a severe threat. It has been documented
for at least a decade that the growth of human populations
surrounding parks in east Africa has resulted in transmission of
human gastrointestinal parasites to wild apes [22,23]. However it
is only in the last three years that modern molecular methods have
confirmed longtime fears that habituating wild gorillas and
chimpanzees to human presence would increase rates of human
respiratory pathogen transmission. Not only do phylogenetic
analyses show a close affinity between globally circulating human
viruses and respiratory viruses that killed chimpanzees at two sites
and gorillas at a third [24,25,26], but clinical observations suggest
that respiratory disease may have been a major source of mortality
at four of the longest studied chimpanzee habituation sites
[5,24,27,28]. At a recent workshop on great ape health,
representatives from virtually all gorilla and chimpanzee habitu-
ation sites in attendance reported observing clinical symptoms
consistent with respiratory disease (Symposium on Great Ape
Health, Kampala, Uganda 2009).
The importance of infectious disease as a threat to wild apes
should be measured not just in terms of the number of deaths
caused by disease outbreaks but also in terms of ape population
resilience: the time necessary for a population to recover from
disease mortalities. Population resilience is central to assessing the
disease threat because gorillas and chimpanzees reproduce more
slowly than virtually any other animal on earth, including humans.
Materials and Methods
To characterize mortality rates typical of disease outbreaks in
wild apes we compiled data from sixteen previously published
outbreaks, wherein community size, number infected and the
mortality rate were explicitly reported (Table 1). While the
etiological agent was not always confirmed with laboratory
diagnostics, the class of disease (e.g. respiratory infection versus
hemorrhagic fever) was. The impact of disease from a single
outbreak ranged widely: e.g. respiratory outbreaks had 0–25%
mortality while Ebola Zaire outbreaks exhibited mortality rates of
95% or greater.
To demonstrate the resilience of populations to disease
outbreaks, we used a demographic modeling exercise.
To describe population growth in gorillas we used a discrete,
logistic model:
Ntz1~NtzR  Nt  (K-Nt=K)
We parameterized the model using an estimated demographic rate
(R) for gorillas in the Virunga Mountains of Rwanda. To be
conservative, we used highly optimistic estimates which tended to
overestimate gorilla reproductive potential. They yielded a Leslie
matrix estimate for the annual rate of increase of R=3.7% (Walsh
and Caillaud, unpublished). Using gorillas was conservative in that
chimpanzees have an even lower maximum population growth
rate, probably about 2% per year.
For the population size before disease impact (N), and the
carrying capacity (K), we used estimates from the 1997 Population
and Habitat Viability Analysis (PHVA) for gorillas in Uganda’s
Bwindi National Park [29]. The estimated population size was 320
gorillas, and the carrying capacity estimate (K) was 300–500, so we
used a midpoint of K=400.
Table 1. Sixteen previous disease outbreaks in African great
apes, for which published estimates of mortality are available.
Disease outbreak a(Reference)
Respiratory (Gombe, 2000) 4 [24]
Mange (Gombe, 1997) 6 [24]
Respiratory (Gombe, 1968) 8 [24]
Polio (Gombe, 1966) 10 [24]
Flu-like (Mahale, September 1993) 10.8 [58]
Mystery (Tai, 1993) 10.8 [25]
Ebola Cote d’Ivoire (Tai, 1994) 12.2 [25]
Flu-like (Mahale, December 1994) 14.8 [58]
Respiratory (Gombe, 1987) 17 [24]
Flu-like (Mahale, 2006) 18.5 [28]
Flu-like (Bossou, 2003) 25 [59,60]
STLV or Strep (Tai, 1999) 31.25 [25]
Ebola, (Lossi Chimpanzees) 77 [2]
Ebola (Lossi Gorillas, 2002–2003) 91 [2]
Ebola (Lossi Gorillas, 2003–2004) 96 [2]
Summary of sixteen previously published outbreaks for which the mortality
impact, the percentage mortality in the group, a, is given, or was possible to
estimate. Note that, for many of the outbreaks, the pathogen was not explicitly
identified.
doi:10.1371/journal.pone.0029030.t001
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mortality rate, a, corresponded to the mortality rate observed in a
real outbreak. In each scenario, we seeded the logistic growth
model with an initial, post-outbreak population size of
N0~N-a  N
then iterated the logistic model in annual times steps until gorilla
population size reached the initial population size, N, as a measure
of recovery time. To examine the resilience of gorillas to disease
we considered five disease mortality scenarios that spanned the
mortality rates reported in Table 1, and the resulting trajectories
are shown in Figure 1.
To assess future potential spillover disease risk, we examined
human vaccination rates and reported cases (where available) for
five exemplar great ape range countries using the UNICEF/WHO
2009 global immunization summary [30] and the WHO 2009
WHS (World Health Statistics) [31], for seven diseases known to
be communicable to great apes (Table 2). We also included data
from the United Kingdom, a leading source country for ape
tourists.
We conducted a literature review of human vaccines for
pathogens that were either already known to infect wild apes or
presented a high risk of infection (e.g. respiratory pathogens likely
to be carried by tourists). For each pathogen we scored whether at
least one vaccine was licensed (L) or under development; in the
advanced stage of development (A) if the most advanced vaccine
was in human clinical trials; or in the early stage of development
(E), if the most advanced vaccine was not yet in human clinical
trials but had protected captive non-human primates from
pathogen challenge. We also identified mode of transmission, the
identity of the reservoir host, and the likely duration of vaccine-
induced immunity (Table 3).
Results
We found that the predicted recovery time for this specific gorilla
populationfromasingle diseaseoutbreakrangedfrom5yearsfora
low mortality (4%) respiratory disease outbreak, to 131 years for an
Ebola outbreak that killed 96% of the gorilla population. Even this
bleak picture of resilience for a well-known gorilla population is
highlyoptimistic. The demographicrates,thesimplicity ofrecovery,
and the assumption of only a single outbreak event are
‘conservative’ treatments of the potential problem. In particular,
our approach assumes no further disease introduction or spread
after the initial outbreak and that a population of gorillas will not
collapse at lownumbers (noAllee effects),butrebound andcontinue
stable growth. In addition, in this model, we used a purely
deterministic framework for illustrative purposes. For populations
this small, stochastic population models are likely more appropriate
to understand the potential impact of diseases, particularly in the
context of demographic fluctuations. Recovery of the population
from such a severe impact as our Ebola outbreak simulation is
questionable, meaning that this is a highly conservative illustration,
and must be seen as such.
However, in great apes habituated for tourism, we can expect
frequent introductions of human pathogens. In the case of rapidly
evolving viruses such as influenza and respiratory syncytial virus
(RSV) this is likely to involve multiple distinct strains with little or
no cross-immunity. RSV and human metapneumovirus (hMPV),
are seasonally cycling human respiratory infections, like influenza.
They are often unidentified, due to symptomatic similarity to the
common cold. In the developing world, they also constitute a
major source of infant mortality [32,33], have been confirmed as
sources of substantial chimpanzee mortality at two sites [5,6], and
may well be responsible for the many of the unidentified ‘‘flu-like’’
outbreaks described in Table 1.
Figure 1. Recovery curves for hypothetical outbreak scenarios within a gorilla population. Five outbreaks from Table 1, (Respiratory
(Gombe, 2000), Flu-like (Mahale, 1993), Flu-like (Bossou 2003), STLV or Strep (Tai 1999), Ebola (Lossi, 2003–2004)) are used to demonstrate the
recovery time to initial population size (dashed line), for a given outbreak mortality.
doi:10.1371/journal.pone.0029030.g001
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There is little doubt that the rate of pathogen spillover from
humans to African great apes is increasing. One major reason is
that the lure of tourist revenue is leading national governments to
habituate more ape social groups for tourism. Because of the
scarcity of diagnostic data on exactly which pathogens infect apes
and at what rates it is difficult to rigorously quantify how increased
tourism will translate into increased disease pressure on ape
populations. However, it is possible to quantify the pool of
pathogens that apes in tourism programs are exposed to in terms
of the disease load in both tourists and the national staff that work
in habituation programs. We assessed this disease load in terms of
Table 2. Vaccination coverage (%) and (cases) reported by country (not reported denoted nr).
Disease (Vaccine)/Country Measles (MCV) Mumps Rubella Pertussis (DPT1/DPT3) Polio (Pol3) Tetanus (TT2) TB (BCG)
Congo 67 (84) 0 nr (2) 80/80 (55) 80 (0) 90 (3) 86 (3,552)
Cote d’Ivoire 67 (5) nr nr (48) 93/76 (nr) 75 (0) 76 (31) 94 (14,071)
DRC 79 (55,577) nr nr 95/87 (3,799) 87 (41) 81 (1,153) 94 (66,099)
CAR 62 (49) nr (0) nr (118) 65/54 (2) 47 (0) 54 (68) 74 (nr)
Gabon 55 (0) nr nr (0) 69/38 (nr) 31 (0) 67 (nr) 89 (1,462)
Uganda 68 (3,776) nr nr (605) 90/64 (nr) 59 (0) 85 (1,007) 90 (21,303)
UK 86 (1,022) nr (2 569) nr (31) 97/92 (1,163) 92 (0) nr (4) 75
a (1,639)
aCoverage reported in 2005 European survey [61], as not reported in WHO statistics.
Cases reported for human diseases and vaccination coverage (%) in exemplar great ape range countries (Congo, Cote d’Ivore, Democratic Republic of Congo (DRC),
Central African Republic (CAR), Gabon and Uganda) and a tourist country (United Kingdom (UK)). MCV is a Measles Containing Vaccine, including MMR (Mumps Measles
Rubella); DPT1/DPT3 are the first and third Diptheria, Pertussis and Tetanus vaccinations given, so the rate at which the third is given is likely best representation of
coverage. Similarly for the Polio vaccine, Pol3 is the third in a series given. For Tetanus, the TT2 is the second of five in a series, and TT2 confers up to 5 years of expected
protection, and is usually given to pregnant mothers to prevent neonatal tetanus. The tuberculosis (TB) vaccine, the Bacillus Calmette-Gue ´rin (BCG) attenuated bovine
tuberculosis strain, is thought to be around 80% effective for 15 years, but this is highly dependent on geography and presence of strain types.
doi:10.1371/journal.pone.0029030.t002
Table 3. Vaccinations available for wild ape populations.
Pathogen T WA R ID LS
Measles Virus R * Human L L [62]
Mumps Virus R Human L L [62]
Rubella Virus R Human L L [62]
Influenza Virus R Human S L [62]
Varicella Virus (chickenpox) R Human L L [62]
Respiratory syncitial Virus (RSV) R * Human S E [63]
Human Metapneumovirus R * Human S E [64]
Diptheria Virus R Human L L [62]
Pertussis Virus (whooping cough) R Human L L [62]
Streptoccocus pneumoniae R * Human S L [62]
Hepatitis A Virus F Human L L [62]
Hepatitis B Virus S * Ape L L [62]
Tuberculosis R Human L L [62]
Polio Virus F * Human L L [62]
Rabies Virus B Domestic Dog S L [62]
Ebola Virus ? * Bat? U A [65,66,67]
Anthrax ? * ? L L [62]
Malaria V * Ape U A* [68,69]
Tetanus W ? S L [62]
Simian Immunodificiency Virus (SIV) B,S? * Ape U E* [70]
Dengue Fever Virus V Primate U E [71]
Yellow Fever Virus V Primate L L [62]
Vaccinations available for wild ape populations, by (T) transmission mode (R=Respiratory, B=Bite, F=Fecal, V=Vectorborne, W=Wound, S=Sexual), whether the
pathogen has been explicitly identified in (WA) wild apes (*), the disease (R) reservoir,t h e(ID) immunity duration (Longterm (L), Shortterm (S) or Unknown (U)) of
the vaccination, and (LS) licensing status, as described in the methods (L=Licensed, E=Early experimental, A=Advanced experimental, *=Vaccine for human strain
only).
doi:10.1371/journal.pone.0029030.t003
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five exemplar great ape range countries using the UNICEF/WHO
2009 global immunization summary [30] and the WHO 2009
WHS (World Health Statistics) [31], for seven diseases known to
be communicable to great apes (Table 2). We also included data
from the United Kingdom, a leading source country for ape
tourists.
On one hand, the prevalence data are encouraging, as they do
not reflect the extremely high childhood respiratory disease
(measles, mumps, rubella, pertussis) rates that until recently
characterized equatorial Africa. This is largely due to a massive
push over the last decade to improve vaccination rates [34], with
large-scale international efforts such as the Measles Initiative (the
Measles Initiative: the American Red Cross, UNICEF, the United
Nations Foundation, the United States Centers for Disease
Control and Prevention (CDC) and the World Health Organiza-
tion (WHO)). On the other hand, these data are discouraging, in
the sense that despite a massive infusion of funds, vaccination rates
for target pathogens such as measles have only reached the mid-
60% range (Table 2), and these pathogens continue to circulate in
the region. Measles still kills about 200,000 children each year,
despite a 91% reduction in cases in Africa reported between 2000
and 2006 [35]. This is a cause for concern in that any failure to
sustain funding (particularly problematic in Africa) could result in
a return of the regional massive outbreaks that were characteristic
prior to 2000. Furthermore, the prevalence of circulating acute
respiratory pathogens (e.g. RSV, HMPV) that are not currently
vaccine treatable, is increasing, due to rising rates of international
air travel [36,37]. Chronic diseases such as tuberculosis also
remain a problem in Africa, and Polio has recently made a
resurgence [38]. Moreover, even a developed country such as the
UK shows only a 86% measles vaccination rate; possibly as a
consequence of fears about vaccine safety that have now shown to
be unfounded [39].
The local ‘‘background’’ spillover rate for fecal-oral pathogens is
also increasing due to the combined effects of increased human
population densities around parks, encroachment into protected
areas, habitat degradation, and even habituation, which forces
apes out of protected areas in search of food [23,40]. Protected
areas in East and West Africa are already small islandized parks in
highly populated areas [41,42,43], and Central African protected
areas are destined to follow in coming decades.
Discussion
Infectious disease is a serious a threat to African apes, along with
poaching and habitat loss. This threat is likely to increase as
human disease spillover into wild ape populations intensifies, both
because of rising population pressure around protected areas and
because of increasing ape tourism.
Alternatives for Disease Mitigation
We hope that our overview of past disease impact, population
resilience, and future disease risk illustrates convincingly that
infectious disease is a serious problem for African great apes that
requires a response. The options for this response vary from
‘‘hands off’’ approaches such as educating governments about the
costs of too much tourism, stricter enforcement of health
guidelines for approaching habituated animals, stricter exclusion
of humans from protected areas, and health programs for staff and
local populations, to more interventionist approaches such as
treatment and vaccination of gorillas or chimpanzees. In the
following paragraphs, we attempt to highlight two issues. First, that
the appropriate response(s) depends upon the source of infection,
and second, that cost-effectiveness should be a major consideration
in choosing responses to a given threat.
Optimal rates of tourism
One option for blocking the spillover of human respiratory
viruses might be to entirely stop habituation of gorillas and
chimpanzees for tourism. However, great ape tourism is a
substantial source of revenue for national governments, park
budgets, politically powerful tour operators, and local communi-
ties. Consequently, an outright ban on tourism would not only be
politically impractical but would likely result in the deterioration of
both protective efforts by park management authorities and
compliance with park regulations by local communities. The
increased impact of other threats such as poaching and habitat
degradation would then likely outweigh any benefits of disease
control.
A more promising middle path is to educate local stakeholders
on the fact that tourism revenue is not maximized by maximizing
the number of tourists that visit. It may be useful to view this as a
maximum sustainable yield problem in which harvesting is
replaced with disease impact. Increasing the tourism rate is like
increasing harvest rate, it increases short term revenue but it also
increases the rate of disease introduction and, therefore, reduces
the population growth rate of the exploited species. In other
words, increasing the rate of tourism eventually decreases the
number of gorillas or chimpanzees available for viewing by tourists
and, therefore, decreases tourism revenue. In the long term,
tourism revenue is actually maximized by not bringing too many
people.
There are two impediments to exploiting the maximum
sustainable yield concept. The first is data scarcity. Choosing an
optimal visitation rate requires information about the relationship
between tourist visitation rates and rates of great ape mortality or
reproductive impairment. Long term demographic data are
already available at some sites [24,44], but vigorous efforts need
to be made to improve data collection at other sites, with a
particular emphasis on quantifying the response of birth and death
rates to fluctuations in the rate of tourism. The second impediment
is that the maximum sustainable yield concept is admittedly
somewhat counterintuitive. Consequently, convincing local stake-
holders that restraint is in their long term self-interest will like
require substantial creativity and persistence.
Hygiene and behavior guidelines
A complementary alternative to limiting the number of tourists
is to limit the exposure risk posed by each tourist. Current Best
Practice guidelines [45] include a variety of strategies for limiting
disease spillover, including wearing facemasks, observing mini-
mum approach distances, limiting visit duration, prohibiting
discharge of body fluids (e.g. spitting, defecating) in the forest,
and barring tourists or staff that exhibit symptoms of infection (e.g.
coughing, runny nose, fever) or do not present vaccination records
[46].
While these are well thought out and useful guidelines, there are
again two major obstacles. Firstly, there are currently no published
data on the efficacy of these measures in preventing disease
spillover. For example, studies estimating the distance necessary to
prevent respiratory virus spillover, how long a visit can last, and
whether masks need to be worn only when in close proximity to
apes or at all times, simply do not exist, so current guidelines [45]
are based on ‘‘best guesses’’. This is important because although
the precautionary principle advises making the guidelines as
stringent as possible, the economic imperative pushes in the
opposite direction. Having only a short visit, wearing a hot and
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able to spit or urinate for several hours degrades the tourism
experience and, presumably, both the number of tourists who
want to come and the amount they are willing to pay. Thus, we
are again balancing disease exposure risk with tourism revenue,
which ultimately determines the intensity of other conservation
threats. Quantifying how different rules affect spillover rates is
necessary so that guidelines can be set in a way.
The second, more serious problem, is compliance. Park
authorities and tourist guides have strong economic incentives to
let tourists go without masks, approach too close, stay too long,
and visit when they are ill: both for promoting future tourism and
for obtaining tips. Consequently, strict safety guidelines are not
enforced at most ape tourism sites in Africa [47,48,49]. Thus,
although hygiene and behavior guidelines have great potential,
and should be vigorously pursued, in practice we cannot currently
rely on them as the sole method for protecting habituated
chimpanzees and gorillas from diseases carried by tourists and
tourism personnel.
Exclusion of humans from protected areas
When humans enter protected areas to engage in activities such
as hunting or wood gathering, they may leave potentially
infectious fluids that can infect wild chimpanzees and gorillas
[22,23]. Human feces are a particular problem because fecal
micro and macro-parasites are typically more resistant to
environmental degradation than are other parasites (e.g. respira-
tory viruses). Policing the defecatory habits of people who are
already in the forest illegally is exceptionally difficult. Rather, a
more logistically feasible approach is simply to prohibit all
unauthorized entry into protected areas for apes. In principle,
this is already the policy at most protected areas for African apes.
However, in practice, enforcement is often weak, as evidenced by
high rates of hunting and habitat degradation at many great ape
protected areas. This approach would therefore require an
increase in both personnel to guard park borders, and mechanisms
for enforcement.
Employee and community health programs
Another option for limiting disease spillover is the establishment
of health programs for staff involved in the habituation of apes for
tourism or research, including vaccination, screening and
treatment. This approach has the advantage of both blocking
disease spillover and enhancing employee loyalty. However, it also
entails ethical and economic subtleties that need to be weighed
carefully, such as whether to screen for diseases for which
treatment is unaffordable, and whether treatment for diseases that
are particularly communicable to gorillas and chimpanzees should
receive priority over chronic or non-infectious diseases that are
not. These ethical questions add complexity to what might appear
to be a simple solution.
A further option is the extension of health programs to local
communities surrounding the protected areas in which apes live.
For example, infection of wild apes in Uganda by gastrointestinal
parasites and pathogens appears to occur not just by movement of
humans into protected areas, or of wild apes out, but also through
waterborne transport from upstream villages [22]. This problem
might be addressed by health interventions in local human
populations, such as medication, installation of water filtration
systems and education programs directed at water use and
hygiene. However, we are again faced with economic and ethical
questions: which is more sustainable, an ape treatment program
that could be undertaken by a single park-based veterinarian, or a
much larger public health effort? Community health programs
may have the added benefit of strengthening bonds with local
populations, and adding support to ape conservation programs.
But it is important not to confuse political objectives with the
actual control of disease spillover when community support may
be achieved more cost-effectively. This is particularly important at
the conservation – public health interface, where funding may be
directed by larger agencies with formal missions and objectives
that may not align well with conservation goals.
Treatment
Curative treatment – that is, reactive intervention - is rare or
absent at most ape conservation sites, but plays a regular role in
management in the tiny remnant populations of mountain gorillas
[46,50]. Infection associated with injury is a common cause for
treatment. Gorillas are also periodically treated for parasites such
as sarcoptic mange [51]. Intervention in the form of treatment
may be the most cost-effective means of controlling fecally
transmitted parasites, particularly if efficient methods of oral drug
delivery can be developed (which would minimize safety concerns
associated with darting).
Unfortunately, treatment is currently not a promising measure
for acute outbreaks of respiratory and hemorrhagic viruses. For
instance, there are no licensed anti-viral drugs effective against
hemorrhagic viruses such as Ebola virus, at present. Current anti-
viral drugs also show limited effectiveness against respiratory
viruses, although new, more effective anti-virals are under
development [52,53], and antibiotics can be effective against
secondary bacterial infections. Importantly, the veterinary infra-
structure necessary to effectively implement treatment for great
apes in response to acute outbreaks is substantial. Because
respiratory pathogens spread rapidly through ape communities
[5] and because anti-virals and antibiotics are most effective when
administered early in infection [54], effective control of acute
outbreaks through treatment likely requires both the permanent
presence of veterinary personnel on site and storage of large
numbers of treatment doses. It also presupposes a well-maintained
monitoring system for quickly detecting symptoms and that large
numbers of animals can be quickly, safely, and (perhaps)
repeatedly treated – presumably using hypodermic darts. On site
diagnostic capacity is also particularly important, as inappropriate
treatment (e.g. antiviral drugs for bacterial infection) must be
minimized. This is essential to reduce the risk of evolved drug
resistance, particularly in a context where it may be difficult to
ensure that treatment regimes are completed.
Vaccination
To our knowledge, wild apes have been the object of
population-wide vaccination campaigns on only two occasions:
emergency vaccination efforts to protect chimpanzees from a
presumed polio outbreak at Gombe, Tanzania [7] and vaccination
of gorillas during a measles outbreak in the Virungas [55]. A
handful of mountain gorillas have also been vaccinated against
tetanus on an opportunistic basis when immobilized for treatment
of snare wounds (C. Whittier, pers. comm.).
Our review of available vaccines suggests that there are
currently a large number of human vaccines that might be used
to protect wild apes (Table 3). We found vaccines for twenty-two
different pathogens that are known to, or could potentially
threaten wild apes, of which sixteen vaccines are already licensed.
We emphasize that this is not an exhaustive list, merely our best
guess at which vaccine preventable diseases were of greatest threat
to wild apes. In our findings, vaccines for respiratory pathogens
were the most common, and humans were the most common
reservoir host.
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simply getting the vaccine into wild gorillas and chimpanzees. In
the long term, the most desirable means of vaccine delivery is oral:
that is packaging the vaccine in a bait that is eaten by gorillas and
chimpanzees. However, oral baiting involves a series of technical,
financial and political challenges that limits its near term potential.
For instance, although using a natural fruit as a bait might seem
ideal, the acids in the fruit can rapidly degrade the vaccine. In
order to avoid transmission of other human pathogens, baits also
need to be packaged under sterile conditions, which is difficult in
the field. Thus, an artificial, manufactured bait may be the best
solution, particularly if large numbers of baits are to be distributed
(e.g. to unhabituated animals). Both finding an artificial bait that
wild apes will eat, and formulating vaccines in heat stable,
environmentally robust forms that can be packaged in baits, are
non-trivial technical tasks.
Baiting also introduces additional safety concerns, as vaccines
that are most effective for oral delivery are typically replicating.
That is, they are infectious agents in which viral reproduction has
been attenuated but are still capable of causing a mild infection in
the target animal. One fear is that under uncontrolled field
conditions and in immunologically stressed wild animals, such
vaccines could cause severe infections or mutate to more virulent
forms. This risk is magnified when the baits may be consumed by
non-target species in which the vaccine has not been studied. This,
in turn, necessitates higher standards of safety testing than that for
vaccines delivered through other means (e.g. by hypodermic dart)
and thus raises the costs of oral vaccination. The cost of baiting is
also increased because a large number of vaccine doses (e.g. 100–
1,000) might need to be distributed for every dose actually
consumed by an ape.
Having duly mentioned these safety and cost concerns, we think
that with careful attention they can be overcome. For instance, the
deployment of hundreds of millions of oral baits led to the virtual
eradication of fox rabies in Europe with almost no recorded
spillover into humans [56]. Likewise, oral vaccination seems the
best option in the long run because it might allow the vaccination
of a large number of unhabituated apes against spillover pathogens
such as Ebola and (in the future) enzootic pathogens such as SIV,
as well as repeated vaccination of habituated apes against rapidly
evolving human respiratory pathogens.
In the meantime, the best way forward seems to be vaccine
delivery using a hypodermic dart. Darting is not without problems,
most prominently the risk of injury to darter and dartee. But
several decades of darting mountain gorillas [46,57] suggest that
these risks can be minimized, particularly because vaccination of
gorillas and chimpanzees does not require immobilization. Taking
an incremental approach with darting would allow us to develop
the epidemiological assays and field protocols to insure that wild
apes can be vaccinated safely and effectively before moving to the
more complex challenges of oral vaccination.
Some readers may object to vaccination on the grounds that the
conservation objective should be to maintain the ‘‘natural
balance’’. Consequently, we should only be concerned with
diseases introduced by humans. However, modern human
activities are now upsetting the ‘‘natural balance’’ in Equatorial
Africa in massive and unprecedented ways. The extraction of
timber, oil, and minerals for export to developed countries is
destroying vast tracts of habitat. The jobs created by these export
industries, and the food and medicines imported from developed
countries have allowed local human populations to explode to
many times their historic levels, creating unprecedented demand
for agricultural land and firewood as well as a cash market for
bushmeat. Ecological communities and ecosystems are so affected
by local, regional and global level anthropogenic impact that we
suggest that it is no longer clear what ‘‘natural’’ means. Thus, even
for pathogens such as Ebola, SIV, or malaria, which are originally
enzootic, we now likely need to intervene in ‘‘natural’’ diseases
that handicap the resilience of wild ape populations to other
threats.
On a more practical level, direct health interventions for great
apes could be highly cost-effective. For example, treatment of the
relatively small number (at most hundreds) of gorillas or
chimpanzees in a park that is heavily affected by fecal pathogen
spillover would be much less expensive than health programs
directed at thousands or tens of thousands of people living
adjacent to the park. Although perceptions of the costs of
vaccination are dominated by the tens of millions of dollars
invested in developing vaccines for the human market, the per-
dose price of many licensed vaccines is very modest: often only a
few dollars. Vaccination is likely cost-effective as it would not
require as much veterinary infrastructure as is necessary for
treatment, and can be conducted under non-emergency condi-
tions. In addition, vaccination would not require such a high level
of sustained disease surveillance or the on-site maintenance of
permanent veterinary teams, diagnostic capacity, or large
standing stocks of drugs. In fact, a single roving vaccination
team might cover many great ape sites. These low overhead costs
thus give vaccination a high potential for sustainability, once
vaccines are made available.
Tourism provides a substantial amount of the revenue for
conservation of African great ape populations. Thus it is very hard
to limit this route of disease spillover to great apes. To some extent,
the disease threat to African apes could be diminished through
non-interventionist approaches such as limitations on tourist
numbers and behavior or staff and community health programs.
However, non-interventionist approaches alone seem unlikely to
entirely contain the disease threat. To be effective, limits on tourist
numbers and behavior must be rigorously enforced; unfortunately,
enforcement is notoriously lax at ape tourism sites. This problem is
compounded by the fact that tactics aimed at preventing disease
spillover from tourists tend to conflict directly with the profit
motive. Additionally, programs focused on preventing human
disease spillover do not address the threat posed by non-human
diseases (e.g. Ebola, malaria, SIV, or hepatitis B), which have a
major impact on ape population growth rates.
Based on our research here, we suggest that the great ape
conservation community should pursue and promote treatment
and vaccination, as weapons in the arsenal for fighting the decline
of African apes. This should include rigorous assessments of both
safety and cost-effectiveness, and should emphasize program
sustainability, with particular attention to the training of African
veterinary personnel. Field studies on safe and efficient methods
for delivering treatments and vaccines orally should be a priority,
but there is also a critical need for studies evaluating the cost-
effectiveness of all ape conservation strategies in terms of their
marginal effects on ape viability.
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